Skip to main content
x

Recent articles

Concentra picks up a new Cargo

The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.

Chia Tai broadens its biparatopic breast cancer approach

The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.

Licensing analysis: big deals bolster biotech

PD-(L)1 x VEGF bispecifics prove a big draw.

Conjugates dominate human trial entries

ADCs newly into human trials include Lilly's PTK7 and two bispecifics.

Safety remains the key metric for Cogent

Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.

Regeneron enters the T-cell engager arena

Lynozyfic could have an edge over rival BCMA-targeting bispecifics.